¶ Tirzepatide
Description: Tirzepatide is a "twincretin" dual GIP and GLP-1 receptor agonist that delivers significant weight loss, glycemic control, and a broad range of metabolic and cardiovascular benefits. It represents a new class of pharmacological intervention, offering results that approach bariatric surgery in magnitude.
¶ At a Glance
What is it?
Tirzepatide (brand names Mounjaro, Zepbound) is a first-in-class dual agonist peptide that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Unlike semaglutide (Ozempic/Wegovy), which targets only GLP-1, tirzepatide mimics the action of two natural incretin hormones to produce synergistic effects on satiety, insulin secretion, and fat metabolism [1][2].
Primary Benefits
Unprecedented weight loss (up to 22.5% of body weight in 72 weeks for non-diabetic individuals) and profound improvements in glycemic control, lipid profiles, and cardiovascular risk factors [3][4]. It also shows emerging benefits in heart failure, sleep apnea, kidney health, MASH resolution, and neuroprotection.
Why use it?
Tirzepatide is currently the most potent pharmacological intervention for weight loss and Type 2 diabetes management available, offering results that approach bariatric surgery. Beyond weight loss, extensive clinical data supports its role in improving cardiovascular, metabolic, and renal health, with growing evidence for neuroprotective effects.
¶ 1. Molecular Details: Structure and Biased Agonism
Tirzepatide is a linear, 39-amino acid synthetic peptide with a unique molecular architecture designed for enhanced efficacy and sustained action [5].
¶ 1.1. Amino Acid Sequence and Fatty Acid Modification
The peptide sequence of tirzepatide is based on the native GIP sequence, but engineered with modifications that allow it to bind and activate both GIP and GLP-1 receptors. A critical feature of its design is the attachment of a C20 diacid fatty acid moiety (eicosanedioic acid) via a lysine residue. This acylation allows tirzepatide to bind strongly to serum albumin, which protects it from enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP). This albumin binding significantly extends its half-life to approximately 5 days, enabling convenient once-weekly subcutaneous administration [1:1][2:1].
¶ 1.2. Imbalanced Affinity and Biased Signaling
Tirzepatide is not a simple "balanced" dual agonist; instead, it exhibits imbalanced affinity and biased signaling at its target receptors [6][7].
- GIP Receptor (GIPR): Tirzepatide binds to the GIPR with high affinity and acts as a full agonist, comparable to native GIP [5:1].
- GLP-1 Receptor (GLP-1R): It binds to the GLP-1R with approximately 5-fold weaker affinity compared to native GLP-1 [1:2].
This imbalanced binding profile is strategic. At the GLP-1 receptor, tirzepatide exhibits biased agonism, preferentially stimulating the cyclic AMP (cAMP) pathway (responsible for insulin secretion and metabolic benefits) while recruiting significantly less beta-arrestin compared to native GLP-1 [8][6:1]. Reduced beta-arrestin recruitment is associated with less receptor internalization and desensitization, potentially maintaining sustained GLP-1 receptor activity and reducing common gastrointestinal side effects, thereby enhancing its overall therapeutic index [9][2:2].
¶ 2. Protocol & Dosing
Tirzepatide is administered once weekly via subcutaneous injection. A slow dose titration is crucial to minimize gastrointestinal side effects.
| Variable | Recommendation |
|---|---|
| Dosage | Start: 2.5 mg/week Max: 15 mg/week |
| Frequency | Once Weekly |
| Cycle | Continuous (Chronic management is generally required for sustained benefits) |
| Route | Subcutaneous Injection (Abdomen, Thigh, Arm) |
¶ Standard Titration Schedule
Tirzepatide requires a slow titration to mitigate GI side effects. Do not rush the schedule.
- **Month 1:** 2.5 mg once weekly (Initiation dose, not typically therapeutic for weight loss)
- **Month 2:** 5.0 mg once weekly
- **Month 3:** 7.5 mg once weekly
- **Month 4:** 10.0 mg once weekly
- **Month 5:** 12.5 mg once weekly
- **Month 6+:** 15.0 mg once weekly (Maximum maintenance dose)
Note: Many users stay at lower doses (5mg, 7.5mg, or 10mg) if they continue to see results and want to minimize side effects, as higher doses are associated with increased risk of adverse events.
¶ 2.1. Compounding Issues and FDA Warnings
The FDA has issued explicit warnings regarding compounded versions of tirzepatide [10]. Compounded drugs are not FDA-approved, are not subject to the same rigorous safety and efficacy reviews as approved medications, and may contain impurities or incorrect dosages. Patients are strongly advised to only use FDA-approved tirzepatide products (Mounjaro or Zepbound) to ensure safety and efficacy. The use of salt forms (e.g., tirzepatide acetate) in compounding is also a significant concern, as these are not the active pharmaceutical ingredient in the approved products.
¶ 3. Benefits (The "Why")
Tirzepatide offers a broad spectrum of benefits, making it a powerful therapeutic agent for metabolic and cardiovascular health.
¶ 3.1. Unmatched Weight Loss
Tirzepatide has set new benchmarks for medical weight management.
- Non-Diabetic Adults (SURMOUNT-1): Participants achieved an average weight loss of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) over 72 weeks [3:1][4:1]. Notably, over 63% of participants on the highest dose achieved >20% weight loss, a magnitude previously considered achievable only with bariatric surgery [3:2].
- Type 2 Diabetes and Obesity (SURMOUNT-2): Patients with both conditions experienced a mean weight reduction of 15.7% on the 15 mg dose over 72 weeks [11][12].
- Sustained Weight Loss (SURMOUNT-4): Continued tirzepatide treatment for 88 weeks resulted in a total mean weight loss of 25.3%, demonstrating the need for chronic therapy to maintain benefits [13][14]. The SURMOUNT-3 trial further showed that tirzepatide added to intensive lifestyle intervention resulted in 26.6% total weight loss [15][16].
¶ 3.2. Glycemic Control (Type 2 Diabetes)
For individuals with Type 2 Diabetes, tirzepatide provides superior glycemic control.
- HbA1c Reduction (SURPASS Program): In head-to-head trials against semaglutide (SURPASS-2) and insulin glargine (SURPASS-4), tirzepatide consistently achieved greater reductions in HbA1c, with reductions up to -2.30% [17][18]. Many patients achieved normoglycemia (HbA1c < 5.7%) [17:1].
- Insulin Sensitivity: It significantly improves both hepatic and peripheral insulin sensitivity, addressing a core pathology of Type 2 Diabetes [1:3].
¶ 3.3. Cardiovascular Health
Tirzepatide offers significant cardiovascular protection and risk factor modification.
- Heart Failure with Preserved Ejection Fraction (HFpEF) (SUMMIT Trial): In patients with obesity and HFpEF, tirzepatide demonstrated a 38% reduction in the risk of cardiovascular death or worsening heart failure events (HR 0.62) [19].
- Major Adverse Cardiovascular Events (MACE) (SURPASS-CVOT): The trial confirmed non-inferiority to dulaglutide for MACE (CV death, MI, stroke) and showed trends towards superiority, with a Hazard Ratio of 0.92 [20][21]. All-cause mortality was significantly lower in the tirzepatide group (HR 0.84) [21:1].
- Blood Pressure: Reductions in systolic blood pressure of 6–8 mmHg and diastolic blood pressure of 4–5 mmHg are commonly observed [22][23].
¶ 3.4. Kidney Health
Emerging evidence suggests tirzepatide offers benefits for kidney function.
- Diabetic Kidney Disease (TREASURE-CKD): Ongoing trials (e.g., TREASURE-CKD, NCT05536804) are specifically evaluating renal outcomes. Preliminary data from earlier studies and post-hoc analyses suggest tirzepatide slows the decline of eGFR and reduces albuminuria (UACR) more effectively than insulin glargine, indicating a significant reduction in the risk of serious kidney-related outcomes [24][25].
¶ 3.5. Sleep Apnea Remission
The SURMOUNT-OSA trials demonstrated significant improvements in obstructive sleep apnea (OSA).
- Apnea-Hypopnea Index (AHI) Reduction: Tirzepatide reduced the AHI by approximately 27.4 to 30.4 events per hour (depending on PAP therapy use) compared to placebo, leading to improved sleep quality and oxygenation [26][27][28]. This led to FDA approval for the OSA indication under the brand Zepbound.
¶ 3.6. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Resolution
Tirzepatide has shown promise in improving liver health.
- SYNERGY-NASH Trial: In patients with biopsy-proven MASH and fibrosis, high-dose tirzepatide led to MASH resolution in up to 62% of patients without worsening of liver fibrosis, compared to 10% with placebo [29][30].
¶ 3.7. Neuroprotection (Emerging)
There is growing excitement about the "neuro-metabolic" link and the potential for tirzepatide to offer neuroprotective benefits.
- Dementia Risk Reduction: Large retrospective studies suggest that patients on GLP-1/GIP therapies like tirzepatide had a 37% lower risk of developing dementia compared to those on other diabetes drugs [31][32].
- Mechanism: Preclinical studies indicate tirzepatide may reduce neuroinflammation, amyloid-β deposition, and tau hyperphosphorylation, while improving brain glucose metabolism and neuronal insulin signaling via pathways like PI3K/AKT [33][34].
¶ 4. Evidence & Science
¶ 4.1. Human Effect Matrix (Evidence Summary Table)
| Outcome | Magnitude | Evidence Quality | Consistency | Citation |
|---|---|---|---|---|
| Weight Loss (Non-Diabetic) | High (↓20.9-22.5%) | High (SURMOUNT-1, SURMOUNT-3) | High | [3:3][4:2][15:1][16:1] |
| Weight Loss (T2D) | High (↓14.7-15.7%) | High (SURMOUNT-2) | High | [11:1][12:1] |
| HbA1c Reduction | High (↓2.1-2.3%) | High (SURPASS Program) | High | [17:2][18:1] |
| HFpEF Events | Moderate (HR 0.62) | High (SUMMIT) | High | [19:1] |
| Sleep Apnea (AHI) | High (↓27.4-30.4 events/hr) | High (SURMOUNT-OSA) | High | [26:1][27:1][28:1] |
| MASH Resolution | High (62% resolution) | Moderate (SYNERGY-NASH Phase 2) | High | [29:1][30:1] |
| Dementia Risk | Moderate (↓37%) | Moderate (Retrospective Cohort Studies) | High | [31:1][32:1] |
¶ 4.2. Key Studies
- SURMOUNT-1 (2022): The landmark Phase 3 trial in 2,539 adults with obesity (without diabetes). Established the 15 mg dose as capable of inducing >20% weight loss, showing superiority over placebo with a similar safety profile to GLP-1 mono-agonists [3:4][4:3].
- SURPASS-2 (2021): Head-to-head comparison with semaglutide (1 mg). Tirzepatide (all doses) was superior to semaglutide in both HbA1c reduction and weight loss [17:3][18:2].
- SUMMIT (2024): A groundbreaking trial for Heart Failure with Preserved Ejection Fraction (HFpEF). Tirzepatide reduced the risk of worsening heart failure events or CV death by 38% (HR 0.62; p=0.026) [19:2].
- SURMOUNT-OSA (2024): Demonstrated significant reduction in the Apnea-Hypopnea Index (AHI) by approximately 27.4 to 30.4 events per hour in patients with obstructive sleep apnea and obesity, leading to FDA approval [26:2][27:2][28:2].
- SYNERGY-NASH (2024): Phase 2 trial showing MASH resolution in up to 62% of patients without worsening of liver fibrosis, highlighting its potential for liver health [29:2][30:2].
- SURPASS-CVOT (2025): Provided definitive cardiovascular safety data, confirming non-inferiority to dulaglutide for MACE and showing lower all-cause mortality [20:1][21:2].
¶ 5. Comparisons
¶ Tirzepatide vs. Semaglutide (Ozempic/Wegovy)
Head-to-head data consistently shows tirzepatide as the more potent agent for weight loss and glycemic control.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | Selective GLP-1 Agonist | Dual GIP/GLP-1 Agonist |
| Weight Loss (Max) | ~15-17% (Wegovy 2.4mg) | ~20-25% (Zepbound 15mg) |
| A1c Reduction | High (Ozempic 1mg) | Very High (Superior in SURPASS-2) |
| Direct Comparison (Weight Loss) | -13.7% (SURMOUNT-5, 2.4mg) | -20.2% (SURMOUNT-5, 15mg) |
| Side Effects | Nausea common | Nausea common (potentially slightly higher during titration) |
| Cost/Availability | High / Shortages | High / Shortages |
Verdict: Tirzepatide consistently demonstrates superior efficacy in both weight loss and HbA1c reduction in direct head-to-head trials (SURPASS-2, SURMOUNT-5) [17:4][18:3][35][36]. While semaglutide has a longer track record of cardiovascular outcome data, tirzepatide's dual mechanism offers broader metabolic benefits.
¶ 6. Safety & Side Effects
¶ 6.1. Common Adverse Events (AEs)
The safety profile of tirzepatide is generally consistent with the incretin class, with gastrointestinal issues being most common, especially during dose escalation.
- Nausea: Very common (17–22%), especially during initiation and dose escalation [17:5].
- Gastrointestinal Distress: Diarrhea (13–16%), constipation (6–7%), vomiting (6–10%), abdominal pain [17:6].
- Fatigue: Often linked to reduced caloric intake.
- Injection Site Reactions: Mild redness or itching.
¶ 6.2. Serious Warnings & Contraindications
- **Thyroid C-cell Tumors**: Boxed warning for Thyroid C-cell tumors. Do NOT use if you have a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [^139].
- **Pancreatitis**: Acute inflammation of the pancreas; requires immediate cessation if suspected [^141].
- **Gallbladder Disease**: Gallstones (cholelithiasis) and cholecystitis have been reported, particularly with rapid weight loss [^141].
- **Hypoglycemia**: Rare in non-diabetics; risk increases if used with insulin/sulfonylureas [^36].
- **Gastroparesis**: Tirzepatide delays gastric emptying; use with caution in patients with pre-existing severe GI disease.
¶ 6.3. Muscle Loss Mitigation & Body Composition
Rapid weight loss with any intervention, including tirzepatide, can lead to a reduction in lean muscle mass alongside fat mass.
- Body Composition Data (SURMOUNT-1 Substudy): A DXA substudy showed that approximately 74.5% of total weight loss was fat mass, while 25.5% was lean mass [37][38]. This ~3:1 fat-to-lean mass loss ratio is consistent with metabolically healthy weight loss observed with caloric restriction and exercise.
- Mitigation: To minimize lean muscle loss, patients are strongly advised to engage in regular resistance training and ensure adequate protein intake (typically 1.6-2.2 g/kg body weight per day) [37:1]. Monitoring changes in body composition using methods like DEXA lean mass ratio can help guide nutritional and exercise strategies.
¶ 7. Legal Status
- FDA: Approved. Marketed as Mounjaro for Type 2 Diabetes (May 2022) and Zepbound for Chronic Weight Management (Obesity/Overweight, November 2023) and Obstructive Sleep Apnea (December 2024/January 2025) [39][40][11:2][41].
- WADA: Prohibited. Tirzepatide is listed under S4 (Hormone and Metabolic Modulators) by the World Anti-Doping Agency. Athletes are banned from using tirzepatide at all times (in and out of competition).
¶ References
PubMed Central. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. https://pmc.ncbi.nlm.nih.gov/articles/PMC7526454/ ↩︎ ↩︎ ↩︎ ↩︎
PubMed Central. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. https://pmc.ncbi.nlm.nih.gov/articles/PMC7526454/ ↩︎ ↩︎ ↩︎
ACC. (2022). SURMOUNT-1. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/08/04/15/32/SURMOUNT-1 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Medthority. (2022). SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight. https://www.medthority.com/news/2022/6/surmount-1-results-published-in-the-new-england-journal-of-medicine-show-tirzepatide-achieved-between-16.0-and-22.5-weight-loss-in-adults-with-obesity-or-overweight.--eli-lilly ↩︎ ↩︎ ↩︎ ↩︎
PNAS. (2022). Tirzepatide is a potent and selective dual GIP and GLP-1 receptor agonist. https://www.pnas.org/doi/10.1073/pnas.2116506119 ↩︎ ↩︎
PubMed. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. https://pubmed.ncbi.nlm.nih.gov/32730231/ ↩︎ ↩︎
ResearchProfiles. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. https://researchprofiles.ku.dk/en/publications/tirzepatide-is-an-imbalanced-and-biased-dual-gip-and-glp-1-recept/ ↩︎
Willard, F. S., et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532. https://doi.org/10.1172/jci.insight.140532 ↩︎
Research Profiles. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. https://researchprofiles.ku.dk/en/publications/tirzepatide-is-an-imbalanced-and-biased-dual-gip-and-glp-1-recept/ ↩︎
FDA. (2024). FDA Warns of Safety Risks with Compounded Tirzepatide. https://www.fda.gov/drugs/human-drug-compounding/fda-warns-safety-risks-compounded-tirzepatide ↩︎
Healio. (2023). SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes. https://www.healio.com/news/endocrinology/20230624/surmount2-tirzepatide-confers-about-15-weight-loss-in-adults-with-obesity-and-diabetes ↩︎ ↩︎ ↩︎
HCP Live. (2023). SURMOUNT-2: Tirzepatide Demonstrates Body Weight Lowering Effects in T2D. https://www.hcplive.com/view/surmount-2-tirzepatide-demonstrates-body-weight-lowering-effects-in-t2d ↩︎ ↩︎
Aronne, L. J., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/ ↩︎
PubMed. (2023). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/38078870/ ↩︎
PR Newswire. (2023). Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies. https://www.prnewswire.com/news-releases/tirzepatide-demonstrated-significant-and-superior-weight-loss-compared-to-placebo-in-two-pivotal-studies-301887287.html ↩︎ ↩︎
Lilly Investor. (2023). Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies. https://investor.lilly.com/news-releases/news-release-details/tirzepatide-demonstrated-significant-and-superior-weight-loss ↩︎ ↩︎
Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385, 503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
NEJM. (2021). SURPASS-2 Full Text. https://www.sochob.cl/web1/wp-content/uploads/2022/03/Tirzepatide-versus-Semaglutide-Once-Weekly-in-Patients-with-Type-2-Diabetes.pdf ↩︎ ↩︎ ↩︎ ↩︎
Eli Lilly. (2024). Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity (SUMMIT). [Press Release]. https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-successful-phase-3-study-showing-benefit ↩︎ ↩︎ ↩︎
TCTMD. (2025). Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial (SURPASS-CVOT). https://www.tctmd.com/news/tirzepatide-matches-dulaglutide-large-cv-outcomes-trial-surpass-cvot ↩︎ ↩︎
PubMed. (2024). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/41406444/ ↩︎ ↩︎ ↩︎
ResearchGate. (2025). Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure. https://www.researchgate.net/publication/377976780_Tirzepatide_Reduces_24-Hour_Ambulatory_Blood_Pressure_in_Adults_With_Body_Mass_Index_27_kgm2_SURMOUNT-1_Ambulatory_Blood_Pressure_Monitoring_Substudy ↩︎
PubMed. (2024). Effect of tirzepatide on 24-h ambulatory blood pressure in adults with overweight or obesity: a SURMOUNT-1 substudy. https://pubmed.ncbi.nlm.nih.gov/39084707/ ↩︎
Healio. (2025). Tirzepatide reduces albuminuria among adults with type 2 diabetes in SURPASS trials. https://www.healio.com/news/endocrinology/20250210/tirzepatide-reduces-albuminuria-among-adults-with-type-2-diabetes-in-surpass-trials ↩︎
ClinicalTrials.gov. (2022). A Study to Learn How Well Tirzepatide Works and How Safe It Is in People With Chronic Kidney Disease (TREASURE-CKD). https://clinicaltrials.gov/study/NCT05536804 ↩︎
Applied Clinical Trials Online. (2024). Tirzepatide shows significant reduction in severity of obstructive sleep apnea in patients with obesity. https://www.appliedclinicaltrialsonline.com/view/tirzepatide-shows-significant-reduction-in-severity-of-obstructive-sleep-apnea-in-patients-with-obesity ↩︎ ↩︎ ↩︎
ACC. (2024). SURMOUNT-OSA. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2024/06/24/16/16/surmount-osa ↩︎ ↩︎ ↩︎
PubMed. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. https://pubmed.ncbi.nlm.nih.gov/38912654/ ↩︎ ↩︎ ↩︎
PubMed. (2024). Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis: The SYNERGY-NASH Phase 2 randomized controlled trial. https://pubmed.ncbi.nlm.nih.gov/38856224/ ↩︎ ↩︎ ↩︎
Lilly Investor. (2024). Lilly's tirzepatide was superior to placebo for MASH resolution and more (SYNERGY-NASH Phase 2). https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-was-superior-placebo-mash-resolution-and-more ↩︎ ↩︎ ↩︎
Biospace. (2025). GLP-1s Could Protect Against Neurodegeneration, EHR-Based Study Shows. https://www.biospace.com/drug-development/glp-1s-could-protect-against-neurodegeneration-study-finds ↩︎ ↩︎
JAMA Network Open. (2025). Association of Semaglutide and Tirzepatide with Dementia. https://pubmed.ncbi.nlm.nih.gov/40663350/ ↩︎ ↩︎
PubMed Central. (2025). Tirzepatide and Neuroprotection. https://pmc.ncbi.nlm.nih.gov/articles/PMC12159100/ ↩︎
ResearchGate. (2024). Tirzepatide Prevents Neurodegeneration Through Multiple Molecular Pathways. https://www.researchgate.net/publication/377778790_Tirzepatide_prevents_neurodegeneration_through_multiple_molecular_pathways ↩︎
PubMed. (2024). Efficacy and Safety of Tirzepatide Versus Semaglutide for Weight Management in Adults With Obesity: The SURMOUNT-5 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/40353578/ ↩︎
Lilly. (2024). Lilly's tirzepatide demonstrated superior weight loss compared to semaglutide in adults with obesity (SURMOUNT-5). https://www.lilly.com/en-CA/news/press-releases/2024.12.4-tirzepatide-surmount-5-h2h ↩︎
PubMed. (2024). Body Composition Changes With Tirzepatide in Adults With Overweight or Obesity: A Secondary Analysis of the SURMOUNT-1 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/39996356/ ↩︎ ↩︎
PubMed. (2024). Body Composition Changes With Tirzepatide in Adults With Overweight or Obesity: A Secondary Analysis of the SURMOUNT-1 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/39996356/ ↩︎
Wikipedia. (2025). Tirzepatide. https://en.wikipedia.org/wiki/Tirzepatide ↩︎
Drugs.com. (2025). Zepbound History. https://www.drugs.com/history/zepbound.html ↩︎
FDA. (2024). FDA Approves First Medication for Obstructive Sleep Apnea. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea ↩︎